Robert J. Gray

Primary Children's Hospital — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

64h-index26.7kcitations352works2.12yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Breast Cancer Treatment Studies(72), Lung Cancer Treatments and Mutations(60), Advanced Breast Cancer Therapies(55), Colorectal Cancer Treatments and Studies(53), Cancer Genomics and Diagnostics(51)

Publications350 total

Overall side‐effect bother consistently associated with early treatment discontinuation due to adverse events in four clinical trials with various cancer types and treatments
UNC Libraries·2025Open Access
Supplementary Figure 3 from Ipatasertib in Patients with Tumors with <i>AKT</i> Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1K
2025Open Access
Supplementary Figure 1 from Ipatasertib in Patients with Tumors with <i>AKT</i> Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1K
2025Open Access
Supplementary Table 1 from Ipatasertib in Patients with Tumors with <i>AKT</i> Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1K
2025Open Access
Supplementary Figure 2 from Ipatasertib in Patients with Tumors with <i>AKT</i> Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1K
2025Open Access
Data from Ipatasertib in Patients with Tumors with <i>AKT</i> Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1K
2025Open Access
Supplementary Table 3 from Ipatasertib in Patients with Tumors with <i>AKT</i> Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1K
2025Open Access
Supplementary Data 1 from Ipatasertib in Patients with Tumors with <i>AKT</i> Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1K
2025Open Access
Supplementary Table 2 from Ipatasertib in Patients with Tumors with <i>AKT</i> Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1K
2025Open Access
Supplementary Table S1 from Phase II Study of Palbociclib (PD-0332991) in <i>CCND1</i>, <i>2</i>, or <i>3</i> Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1B
2025Open Access
supplementary table TS1 from National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH)
2025Open Access
Overall side‐effect bother consistently associated with early treatment discontinuation due to adverse events in four clinical trials with various cancer types and treatments
Cancer·2025· 2 citedOpen Access
Phase II Study of Vismodegib in Patients With <i>SMO-</i> or <i>PTCH1</i> -Mutated Tumors: Results From the National Cancer Institute Molecular Analysis for Therapy Choice Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Trial (EAY131) Subprotocol T
JCO Precision Oncology·2025
The Early Career Workshop of GR-Amaldi 2025
arXiv (Cornell University)·2025Open Access
PIK3CB Inhibitor GSK2636771 in Cancers With <i>PTEN</i> Mutation/Deletion or Loss of PTEN Protein Expression: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols N and P
JCO Precision Oncology·2025· 1 cited
Race, Ethnicity, and Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative, Node-Negative Breast Cancer in the Randomized TAILORx Trial
UNC Libraries·2025Open Access
Ipatasertib in Patients with Tumors with <i>AKT</i> Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1K
Clinical Cancer Research·2025· 3 citedOpen Access
Abstract GS2-02: Impact of Tamoxifen Only after Breast Conservation Surgery for "Good Risk" Duct Carcinoma in Situ: Results from the NRG Oncology/RTOG 9804 and ECOG-ACRIN E5194 Trial
Clinical Cancer Research·2025
Deep generative computed perfusion-deficit mapping of ischaemic stroke
arXiv (Cornell University)·2025Open Access
Phase II Study of Copanlisib in Patients With PTEN Loss: Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols Z1G and Z1H
JCO Precision Oncology·2025Open Access
page 1 of 18Next →

Frequent Co-authors

Joseph A. Sparano(12), Sunil Badve(9), Keith T. Flaherty(9), Lisa M. McShane(9), David R. Patton(9), Edith P. Mitchell(9), Lyndsay N. Harris(9), Larry Rubinstein(9), Carlos L. Arteaga(9), Barbara A. Conley(9), William C. Wood(8), George W. Sledge(8), Alice P. Chen(8), Shuli Li(8), Stanley R. Hamilton(8), P. Mickey Williams(8), Peter J. O’Dwyer(8), Lynne I. Wagner(7), Jeffrey S. Abrams(7), James A. Zwiebel(7)